Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natalie Kalvoda

Nurse Practitioner, Family Bolingbrook, IL Nurse Practitioner

NPI 1639521669 CMS profile 11222264

420 Remington Blvd Ste 125, Ste 110, Bolingbrook, IL 60440

Open in the dashboard

General payments

$21,614

328 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natalie Kalvoda of Bolingbrook, IL is reported in the CMS Open Payments database as having received $21,614 across 328 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,024 92
2024 General $3,360 59
2023 General $2,432 47
2022 General $3,278 65
2021 General $3,520 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalie Kalvoda
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Natalie Kalvoda were reported at $9,024. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Natalie Kalvoda Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,520 $124 $35–$379 $132
2022 $3,278 $141 $44–$430 $149
2023 $2,432 $154 $49–$476 $160
2024 $3,360 $165 $51–$504 $164
2025 $9,024 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $10,826 228 payments
  2. BIOTRONIK NRO, Inc. $9,709 81 payments
  3. Boston Scientific Corporation $838 14 payments
  4. Vertos Medical, Inc. $150 1 payment
  5. TerSera Therapeutics LLC $58 2 payments
  6. Vertex Pharmaceuticals Incorporated $18 1 payment
  7. Relievant Medsystems, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,725 315 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $7,205 4 payments
  3. Education $684 9 payments
Products named General payments · program years 2021–2025
  1. Prospera Not Applicable $7,725 43 payments
  2. PROCLAIM Neuromodulation $2,423 48 payments
  3. Proclaim IPG $2,070 42 payments
  4. PROCLAIM Neuromodulation $1,760 33 payments
  5. Prospera Not Applicable $1,578 25 payments
  6. ETERNA Neuromodulation $1,194 21 payments
  7. Proclaim DRG IPG $763 11 payments
  8. PROCLAIM Structural Heart $562 16 payments
  9. ETERNA Structural Heart $530 23 payments
  10. PROCLAIM Neuromodulation $474 12 payments
  11. Other $2,393 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,663

Median for Nurse Practitioner: 389

Drug cost

$82,235

Median for Nurse Practitioner: $21,885

Branded share of claims

46.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nucynta Tapentadol Hcl Brand 24 $23,790
Belbuca Buprenorphine Hcl Brand 18 $18,192
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 926 $15,593
Gabapentin Generic 369 $5,692
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 185 $4,636
Fentanyl Generic 34 $2,438
Tizanidine Hcl Generic 196 $1,643
Oxycodone Hcl Generic 72 $1,361
Morphine Sulfate Generic 33 $1,071
Cyclobenzaprine Hcl Generic 82 $995

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$62,161

Medicare's payments for the services billed

Medicare patients

188

Average age 69

Services billed

827

121 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 40%
Ischemic heart disease 37%
Diabetes 36%
COPD 29%
Heart failure 28%
Chronic kidney disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

328 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record